Hemophilia cannot be cured at present, and is primarily managed through medication and the supplementation of coagulation factors for prevention and treatment. Patients should avoid injuries and refrain from using drugs that dilate blood vessels or inhibit platelet aggregation. Additionally, genetic counseling should be provided for both the patient and their family.

Recently, significant progress has been made in the gene therapy for Hemophilia A and B. This article introduces the therapeutic effects of gene therapy for hemophilia and the current clinical application status. It is recommended that patients pay attention to their treatment and adopt appropriate dietary adjustments.

Understand the treatment and daily care for hemophilia, and get professional answers to patients’ questions.

Hemophilia A is a genetic disorder that primarily affects the blood’s ability to clot, leading to excessive bleeding. Patients often experience symptoms such as subcutaneous and muscle bleeding, as well as joint bleeding.

A child of four months old has a hernia and is preparing for surgery. A blood clotting mechanism issue was detected, with Factor XI at 49.8 and Factor XII at 33. The child may have hemophilia. Hemophilia is a genetic bleeding disorder characterized by prolonged bleeding time after minor injuries. The disease is generally incurable, and the key to treatment is to prevent bleeding, regional hemostasis, and prompt supplementation of clotting factors. It is recommended to go to a regular professional hospital for examination and treatment.

Hemophilia is a congenital genetic disorder that primarily affects the blood’s ability to clot.